Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 5/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.35 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL29720335 | 0.84 | EGFR (0.41) | ACHEBCHEEGFRERBB2PSMD14 | |
| SCHEMBL2779536 | 0.83 | PSMD14 (0.44) | PSMD14HSP90AA1MMP2MC4RRAD52 | |
| Iodide SCHEMBL2782130 | 0.82 | PSMD14 (0.43) | PSMD14HSP90AA1MMP2MC4RRAD52 | |
| Trifluoromethanesulfonic Acid SCHEMBL29720434 | 0.71 | BCHE (0.44) | ACHEBCHEEGFRERBB2ALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL29720286 | 0.70 | ACHE (0.47) | ACHEBCHESMN1; SMN2GPR3CA1 | |
| Trifluoromethanesulfonic Acid SCHEMBL29720389 | 0.70 | CA1 (0.42) | ACHEBCHEEGFRERBB2ALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL30851370 | 0.69 | KDM4E (0.44) | ACHEALDH1A1MAPK1SMN1; SMN2GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL1130292 | 0.69 | KDM4E (0.59) | ACHEBCHEALDH1A1GPR3CYP1A2 | |
| Trifluoromethanesulfonic Acid SCHEMBL29720379 | 0.69 | ALDH1A1 (0.46) | ACHEBCHEALDH1A1SMN1; SMN2POLB | |
| Trifluoromethanesulfonic Acid SCHEMBL1455736 | 0.68 | PKM (0.46) | ACHEBCHEEGFRERBB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436249-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-1608617-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7378447-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7326731-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-20060178438-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (IN) | 2006-08-10 | — | — | US | disclosed |
| US-20060154922-A1 | Muscarinic agonists | ELILILLY AND COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
| EP-1608619-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1608617-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| CN-1556788-A | Muscarinic agonists | — | 2004-12-22 | — | — | CN | disclosed |
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| WO-2004094363-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094382-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1436249-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003027061-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154922-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | ACHE 80/4885BCHE 432/4885EGFR 1229/4885 |
| US-20060178438-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | ACHE 80/4885BCHE 432/4885EGFR 1229/4885 |
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | CHRM1, CHRM2, CHRM4 | ACHE 89/4885BCHE 129/4885EGFR 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.